迈威生物涨2.05%，成交额1.10亿元，主力资金净流入607.26万元

Core Viewpoint - Maiwei Biotech's stock has shown significant volatility, with a year-to-date increase of 124.41%, but a recent decline in the last five and twenty trading days [1] Group 1: Stock Performance - As of October 15, Maiwei Biotech's stock price was 45.33 CNY per share, with a market capitalization of 18.114 billion CNY [1] - The stock experienced a 2.05% increase during intraday trading, with a trading volume of 1.10 million CNY and a turnover rate of 1.20% [1] - Year-to-date, the stock has risen by 124.41%, but it has decreased by 7.72% in the last five trading days and 9.74% in the last twenty trading days [1] - Over the last sixty days, the stock has increased by 46.94% [1] Group 2: Financial Performance - For the first half of 2025, Maiwei Biotech reported revenue of 101 million CNY, a year-on-year decrease of 12.43% [2] - The company recorded a net loss attributable to shareholders of 551 million CNY, which is a 23.90% decrease compared to the previous period [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased to 17,900, up by 11.66% from the previous period [2] - The average number of circulating shares per shareholder decreased by 10.44% to 11,379 shares [2] - Notable new shareholders include Hong Kong Central Clearing Limited and Xingquan Helun Mixed A, holding 4.7426 million shares and 3.39 million shares respectively [2]